Targeting VPS35 increases chemotherapy sensitivity in gastric cancer cells via regulation of the NF-κB signaling pathway

Targeted Degradation of ATP7B via a Novel Autophagy-Targeting Chimera Promotes Cuproptosis to Potentiate Anti-Tumor Immunity in Clear Cell Renal Cell Carcinoma.

The RNF186-p62-ATP7B axis is identified as a critical regulator of copper homeostasis in ccRCC and Targeting ATP7B via ATAUTAC offers a potent strategy to induce cuproptosis and sensitize ccRCC to immunotherapy.

TET1-mediated DNA demethylation and transcription activation of MRPS17 induces lung adenocarcinoma through PI3K-AKT-mTOR pathway

This study investigates the role of mitochondrial ribosomal protein S17 in the progression of LUAD, with a specific focus on its interaction with the PI3K-AKT-mTOR signaling pathway and highlights the potential of MRPS17 as a prognostic marker and therapeutic target.

Abstract B041: MEK/ERK-dependent regulation of TFEB in response to chemotherapeutic stress

Our previous studies identified Transcription factor EB (TFEB), a master regulator of autophagy and lysosomal biogenesis, as highly expressed in pancreatic cancer (PDAC) cells, where it exhibits prominent nuclear localization even under basal conditions. Functional studies demonstrated that TFEB depletion in PDAC cel...

Targeting Iron Regulatory Protein 2 in Tumor-associated Macrophages Activates Antitumor Immunity in NSCLC via Modulating SphK1-PD-L1 Axis

IRP2-dependent maintenance of the immunosuppressive TAM phenotype as a promising therapeutic target in NSCLC is identified, finding that IRP2 skewed TAMs toward an immunosuppressive state that promoted tumor cell proliferation and migration, and limited apoptosis.

Targeting FEN1 disrupts EIF4A3-mediated MUC1-C autoregulation: a novel strategy to suppress lung adenocarcinoma progression

The FEN1/EIF4A3/MUC1-C axis is established as a novel mechanism driving LUAD progression by concurrently regulating intrinsic malignancy and extrinsic immune evasion, presenting FEN1 targeting as a promising dual-hit therapeutic strategy.

Niclosamide suppresses breast cancer progression and enhances paclitaxel sensitivity by targeting the ATP6AP1-YY1-XIAP axis.